Trial Profile
A Pilot Study of Weekly Brentuximab Vedotin or Brentuximab Vedotin Plus Nivolumab Every 3 Weeks in Patients With CD30+ Malignancies Refractory to Every ≥ 3 Week Brentuximab Vedotin
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Jan 2024
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary) ; Nivolumab (Primary)
- Indications Lymphoma
- Focus Therapeutic Use
- 12 Dec 2023 Results (n=19; as of 27 Jul 2023) reporting final safety, efficacy and correlative analysis presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 04 Oct 2022 Planned End Date changed from 15 Jan 2024 to 1 Sep 2025.
- 04 Oct 2022 Planned primary completion date changed from 15 Jan 2024 to 1 Sep 2024.